Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Allogeneic Osteoblastic Cells

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Allob

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2021

            Details:

            The Phase I/IIa study was a six-month open-label trial. It evaluated the safety and efficacy of ALLOB in the treatment of delayed-union fractures of long bones.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVD-001

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: NVD-001

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2021

            Details:

            NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform.